Fibra Inn Announces the Signing of a Binding Agreement for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
89
Fibra Inn Announces the Signing of a Binding Agreement for the Sale of Microtel Inn & Suites by Wyndham Culiacán Hotel

MONTERREY, Mexico, July 19, 2018 (GLOBE NEWSWIRE) -- Deutsche Bank Mexico, S.A., Banking institution, Trust Division F/1616 or Fibra Inn (BMV: FINN13 ) (ADR/OTC:DFBRY) (“Fibra Inn” or “the Company”), an internally managed Mexican real estate investment trust specializing in the hotel industry serving the traveler with global brands, announced that it has begun the process for the sale of non-strategic assets, as part of its capital recycling program. As such, it has signed a binding agreement for the sale of the Microtel Inn & Suites by Wyndham Culiacan hotel.

The agreed-upon price was Ps. 85.0 million, and the property has a significantly lower cap rate than the Company’s implied cap rate. This property was originally acquired as part of a hotel portfolio that has performed successfully and has altogether reached a cap rate for the trailing twelve months exceeding 9.5%.

Fibra Inn will invest the transaction proceeds in other projects that offer more attractive profitability, including the purchase and cancellation of certificates.

The Company continues to market the sale of some of its other properties in an orderly and efficient manner, Therefore, we expect to announce additional hotel sales transactions in the future.

The buyer intends to keep the current hotel brand, subject to the approval of the international hotel chain. This will enact the early termination contract for the hotel operator, as well as early termination for the leasing of the non-lodging spaces at no cost for the Company.

“ The capital recycling strategy began a few months ago. With this transaction, Fibra Inn reiterates its commitment to this strategy, by selling assets and using those resources to invest in other projects that are more profitable for the Company and therefore generate additional shareholder value. There are other hotels that we consider to be ideal candidates for sale and as asset managers, we will continue working towards higher efficiency, ” stated Oscar Calvillo, Chief Executive Officer.

About the Company Fibra Inn is a Mexican trust formed primarily to acquire, develop and rent a broad range of hotel properties in Mexico. The Company has signed franchise, license and brand usage agreements with international hotel brands for the operation of global brands as well as the operation of national brands. These hotels enjoy some of the industry’s top loyalty programs. Fibra Inn trades its Real Estate Certificates (Certificados Bursátiles Fiduciarios Inmobiliarios or “CBFIs”) on the Mexican Stock Exchange under the ticker symbol “FINN13”; its ADRs trade on the OTC market in the U.S. under the ticker symbol “DFBRY”.

www.fibrainn.mx

Note on Forward-Looking Statements  This press release may contain forward-looking statements.  These statements are statements that are not historical facts, and are based on management’s current view and estimates of future economic circumstances, industry conditions, Company performance and financial results. Also, certain reclassifications have been made to make figures comparable for the periods. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the Company, are intended to identify forward-looking statements.  Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements.  Such statements reflect the current views of management and are subject to a number of risks and uncertainties.  There is no guarantee that the expected events, trends or results will actually occur.  The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors.  Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In México:   In New York:
Lizette Chang, IRO   Maria Barona / Melanie Carpenter
Fibra Inn   i-advize Corporate Communications
Tel. 52-1-81-1778-5926   Tel. (212)406-3691
lchang@fibrainn.mx     mbarona@i-advize.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 15

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Eco Wave Power Expands Wave Energy Project in Europe

Updated Category News Views 229

Eco Wave Power Initiates Key Infrastructure Enhancements Eco Wave Power Global AB (publ) (NASDAQ: WAVE) is excited to unveil plans for crucial upgrades at its groundbreaking wave energy project. This groundbreaking initiative is set to harness ocean wave energy to produce clean electricity efficiently. Eco Wave Power, recognized as a leading company in onshore wave energy...

Continue Reading
Key Managerial Transactions Reported by Danske Bank A/S

Updated Category News Views 162

Recent Mandatory Transaction Notifications by Danske Bank A/S Danske Bank A/S is committed to transparency in financial transactions involving its managerial personnel. This communication signifies the bank's adherence to the EU Market Abuse Regulation and the requirements set by the Danish Financial Supervisory Authority (FSA) and Nasdaq Copenhagen. Understanding...

Continue Reading
Strategic Insights into Symbotic's Options Market Activity

Updated Category News Views 187

Overview of Options Activity for Symbotic Recently, significant investors have demonstrated a notably bearish outlook on Symbotic. This trend has been evidenced by the options activity surrounding the company's stock, symbolized by SYM. The strong presence of whales entering the market indicates a shift in investor sentiment, with nuances that are crucial for...

Continue Reading
South Coast AQMD Takes Action on Oil Facilities During Violations

Updated Category News Views 267

South Coast AQMD Addresses Oil Site Violations In a determined effort to safeguard public health and air quality, the South Coast Air Quality Management District (South Coast AQMD) has recently taken enforcement action against three oil and gas facilities in Los Angeles. These actions were prompted by public complaints and confirmed violations of air quality regulations,...

Continue Reading
BAM UK & Ireland and LoadSpring Solutions Innovate Project Management

Updated Category News Views 199

BAM UK & Ireland and LoadSpring Solutions Innovate Project Management BAM UK & Ireland, a prominent name in the construction and engineering sector, has taken a bold step forward by partnering with LoadSpring Solutions. This collaboration aims to revolutionize project management through an innovative solution known as LoadSpring INSIGHTS™. This groundbreaking platform...

Continue Reading